Akari Therapeutics PLC (NASDAQ: AKTX) is a clinical-stage biopharmaceutical company developing antibody-drug conjugate therapies targeting cancer. The company generates no revenue from product sales, as disclosed in its 10-K filed March 30, 2026, and funds operations entirely through equity and debt financings. As of the filing date, existing cash was expected to sustain operations only into April 2026, with a going-concern warning in place. Its lead program, AKTX-101, is a Trop-2-targeting ADC incorporating a proprietary non-cleavable L22 linker and a spliceosome modulator payload designated PH1, currently in preclinical development. The company is incorporated as a public limited company in the United Kingdom and lists on Nasdaq. CEO Abizer Gaslightwala assumed the role in March 2025 per a CEO agreement dated March 14, 2025. Akari has filed three provisional patents covering spliceosome modulator mechanisms including oncogenic driver targeting, immunogenic payload activity, and synergy with checkpoint inhibitors.

Revenue model

No product revenue. Operations are funded through equity and debt security financings, including convertible notes and warrant-based instruments. The company may also pursue strategic collaborations, licensing arrangements, and technology asset sales, per the FY2025 10-K.

Products and services

AKTX-101: a Trop-2-targeting antibody-drug conjugate using a proprietary non-cleavable L22 linker and PH1 spliceosome modulator payload, in preclinical development as of the 10-K filed March 30, 2026. Three provisional patents cover spliceosome modulator applications in oncology.

Customers and end markets

No approved products and no commercial customers as of the 10-K filed March 30, 2026. Target end market is oncology, with potential patients dependent on government and private third-party payor reimbursement in the United States, EU, and Australia.

Value-chain role

Preclinical-stage drug developer. Conducts laboratory, in vitro, and non-human primate studies internally or through research partnerships. Has not yet filed an IND for AKTX-101. Seeks collaborative or licensing arrangements for further development funding.

Geographic exposure

Incorporated in the United Kingdom. Listed on Nasdaq in the United States. Regulatory engagement references FDA, MHRA, and EMA, indicating intended development activity across the US, UK, and EU. Reimbursement considerations also noted for Australia.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations Peers: DMK PHARMACEUTICALS Corp NRX Pharmaceuticals Inc Opus Genetics Inc Endexx Corp Eton Pharmaceuticals Inc Johnson & Johnson Journey Medical Corp